# Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines

> **NCT06937944** · PHASE3 · RECRUITING · sponsor: **JHM BioPharma (Tonghua) Co. , Ltd.** · enrollment: 669 (estimated)

## Conditions studied

- Moderate to Severe Glabellar Lines

## Interventions

- **BIOLOGICAL:** Rcombinant botulinum toxin type A for injection（Eveotox)
- **BIOLOGICAL:** OnabotulinumtoxinA (Botox)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06937944
- **Lead sponsor:** JHM BioPharma (Tonghua) Co. , Ltd.
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-30
- **Primary completion:** 2025-12
- **Final completion:** 2026-08
- **Target enrollment:** 669 (ESTIMATED)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06937944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06937944, "Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06937944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*